Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and EPOCH in HTLV-Associated ATLL
NCT04301076Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in adult T-cell leukemia-lymphoma (ATLL), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose. Started Aug 2021; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT04301076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301076.